Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4069497 | 1.00 | DPP4 (0.68) | DPP4CHRM1 | |
| SCHEMBL5840139 | 0.92 | DPP4 (0.73) | DPP4CHRM1 | |
| SCHEMBL5840132 | 0.92 | DPP4 (0.73) | DPP4CHRM1 | |
| SCHEMBL8352603 | 0.90 | DPP4 (0.75) | DPP4CHRM1 | |
| SCHEMBL8351213 | 0.90 | DPP4 (0.54) | DPP4CHRM1 | |
| SCHEMBL8351949 | 0.89 | DPP4 (0.74) | DPP4CHRM1 | |
| SCHEMBL13911758 | 0.89 | DPP4 (0.53) | DPP4CHRM1 | |
| SCHEMBL8351807 | 0.87 | DPP4 (0.71) | DPP4CHRM1 | |
| SCHEMBL1069921 | 0.86 | DPP4 (0.68) | DPP4CHRM1 | |
| SCHEMBL8278518 | 0.86 | DPP4 (0.68) | DPP4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569936-B1 | NOVEL SUBSTITUTED IMIDAZO-PYRIDINONES AND IMIDAZO-PYRIDAZEIONES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-03-18 | — | — | EP | claimed |
| US-7109192-B2 | Substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (DE) | 2006-09-19 | — | — | US | claimed |
| US-20050020574-A1 | New substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH CO. KG (DE) | 2005-01-27 | — | — | US | claimed |
| US-7109192-B2 | Substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (DE) | 2006-09-19 | — | — | US | disclosed |
| US-20050020574-A1 | New substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH CO. KG (DE) | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020574-A1 | New substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | DPP4 1/4885CHRM1 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.